
Astellas Pharma Europe appoints new senior director
pharmafile | August 14, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Astellas, Susan Wood
Astellas Pharma Europe has appointed Dr Susan Wood as senior director, Market Access.
Formerly senior brand director of APEL’s Pain Management franchise, she will now drive the firm’s market access activities. Wood will report directly to Kay Drake, vice president Marketing, Astellas.
Welcoming Susan Wood to her new role, Ken Jones, president and chief executive, Astellas, said: “Sue will be working closely with our affiliates to drive the market access strategy across the Astellas Europe organisation in our key therapeutic areas, focusing on developing evidence-based models from the early stages of R&D until the mature stages of the product lifecycle.”
Commenting on her appointment, Wood said: “Astellas Pharma Europe has recently launched its oncology franchise, we are expecting some 11 products to be in launch or early-growth phase in the next three years. I am very much looking forward to the challenge of supporting the company to achieve its strategic objectives.”
Wood joined Astellas Pharma Europe in 2008 and has over 13 years’ experience in international pharmaceutical marketing, with a particular focus on launch strategies.
She previously held roles with Hoffmann-La Roche in Basel, Biogen in Paris and Sanofi Pasteur in Lyon. Before entering the pharma industry, she worked in clinical research.
Related Content

Astellas and Elpiscience enter collaboration for novel bispecific macrophage engager
Elpiscience Biopharma and Astellas Pharma have announced that they have entered into a research collaboration …

EMA accepts Astellas’ MAA for Zolbetuximab
Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the company’s marketing …

Astellas and Cullgen enter into $1.9bn strategic collaboration to progress protein degraders
Japanese pharmaceutical company Astellas and US-based clinical-stage biopharmaceutical company Cullgen have announced that they have …






